Legfrissebb híreink

Személyre szabott gyógyszerelés – és a betegek együttműködési készsége (2011-10-17.)

Top-line results of the AKROBATS trial reveal greater adherence to statins for patients undergoing genetic testing
Additional study data presented at American Society of Human Genetics provide more insight into patient acceptance of pharmacogenetic testing and research participation.

Forrás: PRNewswire részletek >>

Módosított ketogén diéta: reményt keltő eredmények gyermekkori epilepsziában(2011-10-04.)

Modified Atkins Diet Shows Promise as Treatment for Epileptic Children in Indian Clinical Trial

Atkins Nutritionals, Inc. is pleased to distribute the results of the recent clinical trial in India which demonstrated the effectiveness of a modified Atkins Diet™ in treating infantile spasms, a form of epilepsy, in affected children. The study, published in Seizure: The European Journal of Epilepsy (2011), was conducted at the leading Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.

Forrás: PRNewswire részletek >>

Új képalkotó módszer a Parkinson-kór diagnosztikájában(2011-09-29.)

New Imaging Technology Helps in Diagnosing Parkinson's Disease

Central DuPage Hospital one of 200 hospitals in the U.S. to offer diagnostic tool for patients demonstrating Parkinsonian symptoms

Forrás: PRNewswire részletek >>

Az FDA új gyógyszer törzskönyvezését javasolja a haemolyticus uraemiás szindróma (HUS) kezelésére(2011-09-26.)

FDA Approves Soliris for Rare Pediatric Blood Disorder
U.S. Food and Drug Administration today approved Soliris (eculizumab) to treat patients with atypical Hemolytic Uremic Syndrome (aHUS), a rare and chronic blood disease that can lead to kidney (renal) failure and is also associated with increased risk of death and stroke.

Forrás: részletek >>

A Generex prezentációja egy új, inzulintartalmú buccalis készítményről(2011-09-20.)

Forrás: PRNewswire részletek >>

Az iKnowMed™ és Lynx Mobile® rendszerek integrálásával kialakított onkológiai kemoterápiás kezelőprogram(2011-09-16.)

iKnowMed™ Integrates with Lynx Mobile® to Advance a Comprehensive Chemotherapy Management System. Top-ranked oncology-specific electronic health record now joined with leading drug inventory management system.

Forrás: részletek >>

Az FDA új gyógyszer forgalomba hozatalát engedélyezte a középsúlyos-súlyos fájdalom kezelésére (2011-09-06.)

NUCYNTA® ER (Tapentadol Extended-Release Tablets) Receives FDA Approval for the Management of Moderate to Severe Chronic Pain. Clinical Trial Data Demonstrate Efficacy, Safety and Favorable Tolerability

Forrás: részletek >>

Az FDA jóváhagyta az Adcetris (brentuximab vedotin) törzskönyvi kérelmét Hodgkin-kór és systemás anaplasticus nagysejtes lymphoma (ALCL) kezelésére(2011-08-23.)

FDA Approves Adcetris to Treat Two Types of Lymphoma

SILVER SPRING, Md., Aug. 19, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Adcetris (brentuximab vedotin) to treat Hodgkin lymphoma (HL) and a rare lymphoma known as systemic anaplastic large cell lymphoma (ALCL).

Forrás: részletek >>

Befejeződött a buprenorphin humán III fázisú klinikai vizsgálata, krónikus fájdalommal járó állapotokban(2011-07-26.)

BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study. Reporting of top-line efficacy results anticipated in mid to late September

Forrás: PRNewswire részletek >>

Az EMA új stratégiája az antibiotikum-rezisztenciával kapcsolatosan (2011-07-26.)

European Medicines Agency publishes new strategy on combating antimicrobial resistance. The European Medicines Agency has published a new strategy for 2011-2015 aimed at combating the threat of antimicrobial resistance that may arise from the use of antimicrobials (mainly antibiotics) in animals.

Forrás: EMA részletek >>

Az EMA a Pandemrix vakcina alkalmazásának korlátozását javasolja(2011-07-22.)

European Medicines Agency recommends restricting use of Pandemrix. In persons under 20 years of age Pandemrix to be used only in the absence of seasonal trivalent influenza vaccines, following link to very rare cases of narcolepsy in young people. Overall benefit-risk remains positive.

Forrás: EMA részletek >>

Az FDA jóváhagyta a BRILINTA™ (Ticagrelor) törzskönyvezését az USÁ-ban(2011-07-21.)

FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US. BRILINTA indicated to reduce heart attacks and cardiovascular death in patients with Acute Coronary Syndrome. WILMINGTON, Del., July 20, 2011 /PRNewswire/ -- AstraZeneca (NYSE: AZN) announced today that the US Food and Drug Administration (FDA) has approved BRILINTA™ (ticagrelor) tablets to reduce the rate of heart attack (myocardial infarction [MI]) and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS), compared to clopidogrel.

Forrás: PR Newswire részletek >>

Az FDA áttekinti az orvosi mobil alkalmazásokat(2011-07-20.)

FDA Outlines Oversight of Mobile Medical Applications

Agency seeking public input on its proposed approach

SILVER SPRING, Md., July 19, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced it is seeking input on its proposed oversight approach for certain mobile applications specific to medicine or health care called mobile medical applications ("apps") that are designed for use on smartphones and other mobile computing devices. This approach encourages the development of new apps, focuses only on a select group of applications and will not regulate the sale or general consumer use of smartphones or tablets.

Forrás: PR Newswire részletek >>

A Lilly bemutatja a semagacestat adásával nyert eredményeket, Alzheimer-kór kezelésével kapcsolatos klinikai vizsgálataiban(2011-07-19.)

Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimer's Disease Research

INDIANAPOLIS, July 19, 2011 /PRNewswire/ -- Data were presented today from the first of two Phase III trials of semagacestat, including data from a 32 week follow-up period after dosing was halted in August 2010. Semagacestat is a gamma secretase inhibitor that had been studied as a potential treatment for Alzheimer's disease. Results shown today provided patient outcomes from the active treatment portion of the study and from a modified portion of the study conducted after dosing with semagacestat was stopped. Lilly presented the data during a plenary session at the Alzheimer's Association International Conference 2011 (AAIC 2011) in Paris, France.

Forrás: részletek >>

Az Optimer cég új gyógyszere: DIFICID™ (fidaxomycin), a Clostridium difficile-okozta diarrhoea kezelésére, felnőtteken(2011-07-19.)

Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older. Optimer launches Patient Assistance Program to help eligible patients gain access to DIFICID Tablets
SAN DIEGO, July 18, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the commercial launch of DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in patients 18 years of age and older. In two large Phase 3 clinical studies, DIFICID had clinical response rates at the end of the 10-day treatment period that were non-inferior to oral vancomycin.

Forrás: PR Newswire részletek >>

12 3 4

	TOVÁBBI UBM MEDICA OLDALAK - MAGYARORSZÁG
Medimagister (orvos továbbképzés)	> Online kurzusok > Törvénytár > Hírek > Hasznos linkek
PHARMINDEX (kiadványaink)	> Kiadványaink > PHARMINDEX Mobil > PHARMINDEX PLUS
PHARMINDEX Online (gyógyszer-információ)	> Gyógyszerkereső > Új termékek > Gyógyszertörzs változás > Terápiás irányelvek > Hírek > Jogszabályok
Egészségkalauz (laikus információk)	> Egészségtár > Betegségek - tünetek > Keresők > Kalkulátorok > Orvos válaszol > Friss hírek
UBM Medica	> Cégünkről > Tevékenységünk > Kapcsolat > Nemzetközi cégcsoport